The National Institutes of Health (NIH)/National Heart, Lung and Blood institute (NHLBI) launched an initiative, PVDOMICS (Redefining Pulmonary Hypertension through Pulmonary Vascular Disease Phenomics) that aims to augment the current pulmonary hypertension (PH) classification based on shared biological features. PVDOMICS will enroll 1500 participants with PH and disease and healthy comparators. Enrollees will undergo deep clinical phenotyping, and blood will be acquired for comprehensive omic analyses that will focus on discovery of molecular-based subtypes of pulmonary vascular disease (PVD) through application of high dimensional model-based clustering methods. In addition to an updated, molecular classification of PVD, the phenomic data generated will be a rich resource to the broad community of heart and lung disease investigators. Editorial, see p 1106 PH is a hemodynamic condition that causes increased blood pressure in the pulmonary arteries and the right heart leading to adverse clinical outcomes. The current World Symposium on Pulmonary Hypertension (WSPH) classification of PH is based on a combination of patient characteristics, clinical features, and cardiopulmonary hemodynamics, and these features are used to inform treatment options.1 Aside from heritable pulmonary arterial hypertension, this classification is not tied to molecular or cellular pathobiologic mechanism to explain the pathogenesis of PH. The NIH has a vested interest in understanding the causes and natural history of PH, as well as the discovery of effective treatment options. Since the first large NIH registry of patients with pulmonary arterial hypertension >30 years ago,2 significant advances in scientific knowledge and translational medicine have occurred, highlighting a need for updating the current clinical classification system. The NHLBI has sponsored several workshops focusing on PVD research strategic planning over the past decade. PVD encompasses PH and PVD without PH, for example, pulmonary vasculitis and pathological pulmonary vascular remodeling without hemodynamic criteria for PH. Experts identified the need …

中文翻译：

---

PVDOMICS：一项多中心研究，旨在通过血液动力学提高对肺血管疾病的了解。

美国国立卫生研究院（NIH）/美国国立心肺血液研究所（NHLBI）发起了一项计划，即PVDOMICS（通过肺血管疾病的血液学定义肺动脉高压），旨在基于共享的生物学方法增强当前的肺动脉高压（PH）分类特征。PVDOMICS将招募1500名参与者，让他们拥有PH和疾病以及健康的比较者。入选者将进行深入的临床表型分析，并将采集血液用于全面的omic分析，该分析将重点通过应用基于高维模型的聚类方法来发现基于分子的肺血​​管疾病（PVD）亚型。除了更新的PVD分子分类以外，所生成的形态学数据将为广大心脏和肺部疾病研究者群体提供丰富的资源。社论，请参阅第1106页。PH是一种血液动力学疾病，会导致肺动脉和右心血压升高，从而导致不良的临床结果。当前的世界肺动脉高压研讨会（WSPH）对PH的分类是基于患者特征，临床特征和心肺血流动力学的组合，这些特征可用于为治疗选择提供依据。1除了遗传性肺动脉高压外，该分类还包括与分子或细胞病理生物学机制无关，无法解释PH的发病机理。NIH对了解PH的病因和自然病史以及发现有效的治疗选择有着既得的兴趣。自30年前首例大型NIH肺动脉高压患者登记以来，科学知识和转化医学已取得2项重大进步，突出表明需要更新当前的临床分类系统。在过去的十年中，NHLBI赞助了几场关于PVD研究战略规划的研讨会。PVD涵盖了PH和没有PH的PVD，例如，肺血管炎和病理性肺血管重塑，没有针对PH的血液动力学标准。专家们确定了需求…… 肺血管炎和病理性肺血管重塑，无PH的血流动力学标准。专家们确定了需求…… 肺血管炎和病理性肺血管重塑，无PH的血流动力学标准。专家们确定了需求……